Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

The poster presentation will show interim data for HPN424 from its ongoing dose escalation Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC).